Fpr2: a novel drug target to tackle oxidative stress and inflammation in Alzheimer’s disease

Wickstead, E. 2017. Fpr2: a novel drug target to tackle oxidative stress and inflammation in Alzheimer’s disease. Alzheimer's Research UK Conference. Aberdeen 14 - 15 Mar 2017

TitleFpr2: a novel drug target to tackle oxidative stress and inflammation in Alzheimer’s disease
AuthorsWickstead, E.
TypeConference poster
Abstract

Inflammation and oxidative stress both act as major contributors to Alzheimer’s disease [1,2]. Microglia, the resident immune cells of the central nervous system, are the first line of immunological defence, but can become toxic when chronically activated, leading to extensive neuronal damage [3]. Attenuating or even reversing this may provide neuronal protection against chronic oxidative and inflammatory damage. The aim of this study was to determine whether lipopolysaccharide (LPS)-induced oxidative stress and inflammation could be reduced through activation of the Fpr2 receptor, known to have an important role in the resolution of peripheral inflammation. Immortalised murine microglia (BV2 cells) were stimulated with LPS (50ng/ml) for 1h prior to treatment with the Fpr2 ligand, Cpd43 (100nM). Cytokine (TNFα and IL-10) production was monitored at 24 and 48h. Reactive oxygen species (ROS) were monitored with carboxy-H2DCFDA. LPS was administered for 30 minutes prior to Cpd43, with ROS production analysed every 30 minutes between 1 and 3h.

Treatment with Cpd43 significantly suppressed LPS-induced production of TNFα at 24h and 48h post-exposure. Moreover, Cpd43 treatment significantly enhanced production of IL-10 48h post-LPS treatment. This was a result of the activation of p38 MAP kinase, as determined by western blot analysis. This aligns with previous data investigating Fpr2 activation and signaling [4]. Interestingly however, Cpd43 also reduces LPS-induced ROS production back to baseline levels – something not previously recorded for Fpr2 agonists.

Combined, these data highlight Fpr2 as a novel target to exploit immunomodulatory strategies for the treatment of neurological diseases, but also indicates a combined action, involving the amelioration of oxidative stress.

References

1. Heppner et al. (2015). Nat Rev Neurosci 16: 358-372.
2. Agostinho et al. (2010). Curr Pharm Des 16: 2766-78.
3. Cunningham (2013). Glia 61: 71-90.
4. Cooray et al. (2013). Proc Natl Acad Sci U S A 110: 18232-7.

KeywordsInflammation; Oxidative Stress; Fpr2; Alzheimer's
Year2017
ConferenceAlzheimer's Research UK Conference

Related outputs

Quin-C1: a selective Fpr2 agonist that shifts microglial phenotype following LPS and Aβ1-42 exposure
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2018. Quin-C1: a selective Fpr2 agonist that shifts microglial phenotype following LPS and Aβ1-42 exposure. Alzheimer's Research UK Conference. London 20 - 21 Mar 2018

Reversal of β-amyloid induced microglial activation by an agonist of Fpr2
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2017. Reversal of β-amyloid induced microglial activation by an agonist of Fpr2. British Pharmacological Society: Pharmacology 2017. London 11 - 13 Dec 2017

Activation of the pro-resolving receptor Fpr2 attenuates inflammatory microglial activation
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2017. Activation of the pro-resolving receptor Fpr2 attenuates inflammatory microglial activation. BNA Festival of Neuroscience. Birmingham 10 - 13 Apr 2017 Sage. doi:10.1177/2398212817705279

Fpr2 and neuroinflammation: selective agonists with synergistic anti-oxidative and pro-resolving effects
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2017. Fpr2 and neuroinflammation: selective agonists with synergistic anti-oxidative and pro-resolving effects. World Congress on Inflammation. London 08 - 12 Jul 2017

The formyl peptide receptor 2 (Fpr2) agonist, Compound 43 (Cpd43), attenuates and promotes the release of pro-inflammatory, and anti-inflammatory cytokines, respectively
Wickstead, E., Getting, S.J. and McArthur, S. 2016. The formyl peptide receptor 2 (Fpr2) agonist, Compound 43 (Cpd43), attenuates and promotes the release of pro-inflammatory, and anti-inflammatory cytokines, respectively. British Pharmacological Society: Pharmacology 2016. London 13 - 15 Dec 2016

Permalink - https://westminsterresearch.westminster.ac.uk/item/q4xz3/fpr2-a-novel-drug-target-to-tackle-oxidative-stress-and-inflammation-in-alzheimer-s-disease


Share this
Tweet
Email